Histopathological and immunohistochemical changes induced by Bisphenol A in reproductive tissues of female rat

Background: Bisphenol A [BPA] is an environmental chemical that has been widely used in the manufacture of polycarbonate plastics and epoxy resins for many years. Due to its major applications in the production of plastic food or beverage containers and the coating of food cans, people of different ages are inevitably exposed to BPA in daily life. It is a contaminant with increasing exposure to it and exerts both toxic and estrogenic effects on mammalian cells

Aim of the work: the present study was designated to evaluate the histopathological and immunohistochemical effect of BPA on the histoarchitecture of pituitary ,adrenal, ovarian and uterine axis of female albino rats and the ameliorative effect of antiestrogen drug and stem enhance

Experimental model and methods: 20 female albino rats weighing 100 - 120 g. were kept under observation for about 15 days before the onset of the experiment for adaptation, then the rats were classified into 4 groups 5 rats for each , the first group was left without any treatment for 30 days as negative control group , the second group was administered with 20 mg/kg.bw of BPA for 15 consecutive days as positive control, the third group administered with 20 mg/kg.bw of BPA for 15 consecutive days and then treated with antiestrogen drug as 0.1 mg/100gm.bw for 15 day, the fourth group administered with the same dose for the same period and the treated with stem enhance [4.5 mg/100.bw] for 15 days. All rats are scarified and organs were histologically examined after processing

Results: The results showed that PA has a histopathological effects on vital organs [pituitary, adrenal, ovary, oviduct and uterus] even for a short period with minimal ameliorative effect of antiestrogen drug and stem enhance

Methylmercury inhibits prolactin release in a cell line of pituitary origin

Heavy metals, such as methylmercury, are key environmental pollutants that easily reach human beings by bioaccumulation through the food chain. Several reports have demonstrated that endocrine organs, and especially the pituitary gland, are potential targets for mercury accumulation; however, the effects on the regulation of hormonal release are unclear. It has been suggested that serum prolactin could represent a biomarker of heavy metal exposure. The aim of this study was to evaluate the effect of methylmercury on prolactin release and the role of the nitrergic system using prolactin secretory cells (the mammosomatotroph cell line, GH3B6). Exposure to methylmercury (0-100 μM) was cytotoxic in a time- and concentration-dependent manner, with an LC50 higher than described for cells of neuronal origin, suggesting GH3B6 cells have a relative resistance. Methylmercury (at exposures as low as 1 μM for 2 h) also decreased prolactin release. Interestingly, inhibition of nitric oxide synthase by N-nitro-L-arginine completely prevented the decrease in prolactin release without acute neurotoxic effects of methylmercury. These data indicate that the decrease in prolactin production occurs via activation of the nitrergic system and is an early effect of methylmercury in cells of pituitary origin.

Arginine induces GH gene expression by activating NOS/NO signaling in rat isolated hemi-pituitaries

The amino acid arginine (Arg) is a recognized secretagogue of growth hormone (GH), and has been shown to induce GH gene expression. Arg is the natural precursor of nitric oxide (NO), which is known to mediate many of the effects of Arg, such as GH secretion. Arg was also shown to increase calcium influx in pituitary cells, which might contribute to its effects on GH secretion. Although the mechanisms involved in the effects of Arg on GH secretion are well established, little is known about them regarding the control of GH gene expression. We investigated whether the NO pathway and/or calcium are involved in the effects of Arg on GH gene expression in rat isolated pituitaries. To this end, pituitaries from approximately 170 male Wistar rats (~250 g) were removed, divided into two halves, pooled (three hemi-pituitaries) and incubated or not with Arg, as well as with different pharmacological agents. Arg (71 mM), the NO donor sodium nitroprusside (SNP, 1 and 0.1 mM) and a cyclic guanosine monophosphate (cGMP) analogue (8-Br-cGMP, 1 mM) increased GH mRNA expression 60 min later. The NO acceptor hemoglobin (0.3 µM) blunted the effect of SNP, and the combined treatment with Arg and L-NAME (a NO synthase (NOS) inhibitor, 55 mM) abolished the stimulatory effect of Arg on GH gene expression. The calcium channel inhibitor nifedipine (3 µM) also abolished Arg-induced GH gene expression. The present study shows that Arg directly induces GH gene expression in hemi-pituitaries isolated from rats, excluding interference from somatostatinergic neurons, which are supposed to be inhibited by Arg. Moreover, the data demonstrate that the NOS/NO signaling pathway and calcium mediate the Arg effects on GH gene expression.

[Effect of 3,4-methylenedioxymethamphetamine on pituitary-gonadal hormonized axis in immature male rats]

In recent years, 3,4-methylenedioxymethamphetamine [MDMA] consumption is prevalent among young people. It has adverse effects on central neural system and other organs. This study was done to determine the effect of MDMA on pituitary-gonadal hormonized axis in immature male rats. In this experimental study 35 immature male Wistar rats with approximate weight of 90 +/- 10 gr, age range of 40-45 days were allocated in five [n=7] including experimental I, II, III, control, and shem groups. Animals in the experimental I, II, III have received 2, 4 and 8 mg/kg bw of MDMA intraperitoneally after 14 days, respectively. Animals have received saline normal in shem group while the controls did not receive any substance. The blood samples and testes have collected. The serum FSH, LH, and Testosterone concentrations and testes weight were determined. Data analyzed using ANOVA and Tukey tests. Testosterone hormone concentration significantly increased in experimental groups [4 and 8 mg/kg bw] in comparison with control and shem groups [P<0.05]. Concentrations of FSH and LH in the experimental groups [2 and 4 mg/kg bw] significantly reduced in comparison with shem and control groups [P<0.05]. Testes weight significantly reduced in experimental groups [4 and 8 mg/kg bw] compared to control and shem groups [P<0.05]. This study showed the MDMA has adverse effect on pituitary-gonadal axis and tests weight in immature male Wistar rats

Luteinizing hormone reduction by the male potency herb, Butea superba Roxb.

To determine if Butea superba Roxb., a traditional Thai male potency herb, has androgenic activity in 60-day-old male Wistar rats, we measured its effects on the pituitary-testicular axis and sex organs. Intact and orchidectomized adult male rats were subdivided into five groups (10 rats/group): distilled water, Butea superba (BS)-10, BS-50, BS-250, and testosterone propionate (TP). They received 0, 10, 50, and 250 mg·kg body weight-1·day-1 BS in distilled water by gavage and 6 mg·kg body weight-1·day-1 TP sc, respectively, during the 30-day treatment period. Blood was collected every 15 days and luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone were measured. Changes of weight and histological appearance of sex organs were determined at the end of the 30-day treatment and 15-day post-treatment periods. TP treatment reduced serum FSH and LH levels and significantly increased the weight of the seminal vesicles and epididymis, in accordance with histopathological changes, in both intact and orchidectomized rats. No changes in serum testosterone, LH, and FSH levels were observed in any of the intact rats treated with BS, but a significant increase in seminal vesicle weight was observed only in the BS-250 group. Although a significant reduction in serum LH was detected in the BS-50 and BS-250 groups of orchidectomized rats, no significant change in weight or histology of sex organs was observed. Thus, we conclude that B. superba needs endogenous testosterone to work synergistically to stimulate the accessory sex organ of intact animals and can potentially exhibit an LH reduction effect in orchidectomized animals.

Pituitary toxicity but lack of rat colon carcinogenicity of a DC-magnetic field in a medium-term bioassay.

The present study was designated to evaluate the effect of direct current induced permanent magnetic field (DC-MF) on chemically induced rat colon carcinogenesis. Five experimental groups of male S.D. rats were injected with 1,2-dimethylhydrazine (DMH) subcutaneously, 20 mg/kg b.wt., once a week for four weeks, with exposure to 1 mT DC-MF (12 hours/day) as follows: Before (pre) the carcinogen administration (group 1), simultaneously (group 2), after (post) the carcinogen administration (group 3) and daily from the beginning to the end of the experiment after 12 weeks (group 4). Rats of group 5 served as carcinogen-only treated controls while those of group 6 were non-treated controls. There were no differences in the incidences and multiplicities of colonic aberrant crypt foci (ACF), putative preneoplastic lesions, among all groups except that large foci in group 1 were significantly fewer in numbers than those found in group 5. Proliferating cell nuclear antigen labeling indexes (PCNA-LI) in the colon epithelium were essentially the same in MF-treated and control rats. Histopathological examination showed evident hemorrhage in the pituitary glands of some rats of groups 1-3, and in most rats of group 4. Transmission electron microscopy also revealed ultrastructural changes, but DNA ploidy analysis revealed no carcinogenicity to MF-exposed pituitary glands. Serum levels of AST, ALT, total protein, creatinine, albumin, albumin/globulin ratio and growth hormone levels did not change among the groups. The present study revealed that the action of an artificial MF on rats is not carcinogenic/or cancer-promoting, at least in the present protocol for colon carcinogenesis.

Persistence of hyperprolactinemia after treatment of primary hypothyroidism and withdrawal of long term use of estrogen: are the tuberoinfundibular dopaminergic neurons permanently lesioned?

Uso prolongado de altas doses de estrogênio e a presença de hiperprolactinemia crônica pode, pelo menos no rato, provocar lesão nos neurônios dopaminérgicos tuberoinfundibulares (TIDA) responsáveis pelo controle da secreção de prolactina (Prl). Essa ocorrência, ainda não bem documentada em humanos, pode ter ocorrido em uma paciente em tratamento crônico com contraceptivo oral (OC), que veio para consulta por hipotiroidismo primário, hiperprolactinemia e uma massa hipofisária. Após reposição de hormônio tiroidiano, suspensão do tratamento com o OC e a bromocriptina, essa paciente não manteve níveis normais de Prl, necessitando tratamento contínuo com agonista dopaminérgico, mesmo quando a RM da região selar indicava uma situação normal. A função dos neurônios TIDA foi investigada pelo teste do TRH (200µg IV), realizado antes e após 25mg de carbidopa e 250mg de L-dopa a cada 4 horas por um dia. TSH basal (3,9µU/mL) era normal, enquanto Prl (67,5 ng/mL) estava alta; ambos aumentaram apropriadamente após o estímulo com TRH, com picos de 31,8µU/mL (TSH) e 157,8ng/mL (Prl). Após tratamento com carbidopa/L-dopa, os níveis de TSH (1,6µU/mL) e Prl (34ng/mL) diminuíram e a resposta ao TRH foi parcialmente bloqueada (10,3µU/mL e 61ng/mL, respectivamente). Apesar da resposta normal, discutimos a possibilidade que a persistência da hiperprolactinemia é devida a uma lesão dos neurônios TIDA, produzida pelo longo uso de altas doses de estrogênios e pela presença de hiperprolactinemia crônica.

Ultrastructural studies on the effect of fenthion on pituitary (GTH cells) and testis of Glossogobius giuris. (HAM) during breeding phase.

Pesticide (fenthion) which finds its way into water bodies, bring about physiological changes in aquatic animals, via histomorphology and histopathology of various tissues. In fishes, it induces disorders including hyposecretion of gonadotropin in the PPD and regression of gonads. Light microscopic studies were made on control and treated pituitary (gonadotropin secreting cells-GTH) and testis of Glossogobius giuris (HAM) during spawning phase after exposing them to different (0.05 to 0.5 ppm) sub-lethal concentration of fenthion for a short-term period (24 to 96 hrs). The results indicated alteration in normal histology of gonadotropin secreting cells and testis, reduction in number of sperms and degranulation of GTH cells under light microscopy. Degeneration and fragmentation of cytoplasmic organelles was noticed in GTH cells under electron microscope, with the increase in the sub-lethal concentration of fenthion. Significance of the results is discussed in detail in the manuscript.

Effect of mercuric chloride on circulating hormones in adult albino rats.

The effect of mercuric chloride at two different doses, 0.5 mg/kg body weight (low dose), 1 mg/kg body weight (high dose), for 30 days, was seen on the circulating hormones in the mature male albino rats. Testosterone level was markedly decreased in the low dose (P < 0.01) and high dose (P < 0.001) treated animals. The level of luteinizing hormone (LH) was also reduced in the low dose (P < 0.01) as well as in the high dose (P < 0.001) treated animals. However, follicle stimulating hormone (FSH) and prolactin (PRL) levels were found to be decreased only in the high dose (P < 0. 05) treated animals and no change was observed in the low dose treated animals. The changes in the hormone levels caused by the mercuric chloride treatment suggest the dysfunction of pituitary-testicular axis.

Growth hormone mRNA expression in the pituitary of Bos indicus and Bos taurus x Bos indicus crossbred young bulls treated with recombinant bovine somatotropin

The effects of breed and of recombinant bovine somatotropin (rbST) treatment on growth hormone gene expression were studied in young bulls. The experiment was completely randomized in a [2 x 2]-factorial arrangement, using two levels of rbST (0 or 250 mg/animal/14 days), and two breed groups (Nelore and Simmental x Nelore crossbred). A cDNA encoding Bos indicus growth hormone was cloned and sequenced for use as a probe in Northern and dot blot analyses. Compared to the Bos taurus structural gene, the Bos indicus cDNA was found to begin 21 bases downstream from the transcription initiation site and had only two discrepancies (C to T at position 144-His and T to C at position 354-Phe), without changes in the polypeptide sequence. However, two amino acid substitutions were found for Bubalus spp., which belong to the same tribe. The rbST treatment did not change any of the characteristics evaluated (body and pituitary gland weights, growth hormone mRNA expression level). Crossbred animals had significantly higher body weight and heavier pituitaries than Nelore cattle. Pituitary weight was proportional to body weight in both breed groups. Growth hormone mRNA expression in the pituitary was similar (P>0.075) for both breed and hormonal treatment groups, but was 31.9 higher in the pure Nelore group, suggesting that growth hormone gene transcription regulation differs among these breeds

Prolactin-releasing activity of GHRP-5 (Momany peptide) on lactotrophs in vivo and in vitro

In the present study the in vivo and in vitro effects of GHRP-5 on the PRL-releasing activity in correlation with the morphological changes of lactotroph cells and their transcriptional activity were evaluated. The in vivo treatment (12 micrograms/100 g BW/day for 3 days) of male rats with GHRP-5 does not induce any significant changes in serum PRL levels. In contrast, the addition of GHRP-5 to pituitary cell cultures increased significantly the release of PRL. This effect is enhanced in cell cultures of enriched lactotrophs, increasing significantly the secretion of PRL, the concentrations of which were 50 higher than that of untreated control cells. The administration of GHRP-5 provokes several changes in the fine structure of lactotrophs, compatible with an increased secretory activity. After the GHRP-5 treatment the different lactotroph subtypes persist but the subtype I displaying secretory granules of larger size (500-900 nm) and a significant development of the Golgi apparatus and RER were more frequently observed. These results can be correlated with a significant augmentation in PRL mRNA after the GHRP-5 treatment. In spite of that no variations in serum PRL levels were observed in vivo, following GHRP-5 treatment, the lactotroph population experienced evident fine structure modifications, concordant with an upsurge of PRL synthesis. These observations confirmed a direct action of GHRP-5 on receptors expressed by lactotrophs. The differential actions of GHRP-5 on in vivo and in vitro designs confirm a different effectiveness of this secretagogue to induce PRL secretion.

Fine structure of prolactin cell of female albino rat as affected by some antifertility drugs--a comparative electron microscopic study.

One antioestrogenic compound as well as some antifertility drugs have been administered to female albino rats over a period of six months to study their long term effects on fine structures in PRL cell. Almost in all the cases, the dynamics of hormone synthesis and secretion have been affected. Fine structure is suggestive of activation of synthetic machinery of the cell. The cell picture under the estradiol valerate regimen presents a transitional stage progressing towards involution due to accelerated cell cycle. Sparse granulation, frequent granule extrusion and misplaced exocytosis under the influence of tamoxifen citrate or levonorgestrel + ethinyloestradiol are similar to those observed in adenomatous PRL cell. Fine structural correlates of stepped up synthesis are also observed following chronic progesterogenic influences of progesterone and norethisterone heptanoate, but the magnitude of the change is on a lower scale. All the fine structural changes have been discussed in the context of ultrastructural pathology.

Effect of medroxyprogesterone acetate on thyrotropin secretion in adult and old female rats

Steroid hormones have been implicated in the modulation of TSH secretion; however, there are few and controversial data regarding the effect of progesterone (Pg) on TSH secretion. Medroxyprogesterone acetate (MPA) is a synthetic alpha-hydroxyprogesterone analog that has been extensively employed in therapeutics for its Pg-like actions, but that also has some glucocorticoid and androgen activity. Both hormones have been shown to interfere with TSH secretion. The objective of the present study was to investigate the effects of MPA or Pg administration to ovariectomized (OVX) rats on in vivo and in vitro TSH release and pituitary TSH content. The treatment of adult OVX rats with MPA (0.25 mg/100 g body weight, sc, daily for 9 days) induced a significant (P<0.05) increase in the pituitary TSH content, which was not observed when the same treatment was used with a 10 times higher MPA dose or with Pg doses similar to those of MPA. Serum TSH was similar for all groups. MPA administered to OVX rats at the lower dose also had a stimulatory effect on the in vitro basal and TRH-induced TSH release. The in vitro basal and TRH-stimulated TSH release was not significantly affected by Pg treatment. Conversely, MPA had no effect on old OVX rats. However, in these old rats, ovariectomy alone significantly reduced (P<0.05) basal and TRH-stimulated TSH release in vitro, as well as pituitary TSH content. The results suggest that in adult, but not in old OVX rats, MPA but not Pg has a stimulatory effect on TSH stores and on the response to TRH in vitro

Effect of naloxone on GnRH-induced LH and FSH release in buffalo, Bubalus bubalis.

The effect of naloxone on GnRH-induced LH and FSH release was measured in buffaloes in luteal phase of estrous cycle. Animals were administered intravenously, naloxone/saline (50 mg/injection) every 15 min for 3 hr followed by GnRH (100 micrograms). Peripheral plasma LH and FSH concentrations were measured in blood samples collected at 15 min intervals from 1 hr prior to beginning of naloxone/saline treatment up to 3 hr post GnRH administration and every 30 min for the subsequent 3.5 hr. Between the animals of Group I administered naloxone and those of Group II given saline, GnRH-induced peak LH and FSH concentrations, the total LH and FSH released in response to GnRH, and the time to peak LH and FSH concentrations were not significantly different. The results of the present study suggest the absence of a direct effect of naloxone on pituitary responsiveness to GnRH.

Effects of oncostatin M on hormone release of rat pituitary cells in primary culture

It has become increasingly clear that cytokines play an important role in modulating neuroendocrine regulation, especially in the secretion of corticotropin (ACTH) in the pituitary. Oncostatin M (OSM), a cytokine of IL-6 family has been reported to increase ACTH secretion and pro-opiomelanocortin (POMC) transcription in murine corticotroph pituitary tumor cells (AtT20 cells). The present study was undertaken to determine the effects of OSM on hormonal release in primary culture of rat pituitary cells. Growth hormone or prolactin release was not affected by OSM. OSM (1 nM) stimulated ACTH release (35.1% increase versus control, p>0.001) in dispersed pituitary cells of rat to a lesser extent than in AtT20 cells. Corticotropin releasing hormone (CRH) (10 nM) also induced a 2.3-fold increase of ACTH secretion (p>0.001), but co-treatment of OSM and CRH did not exhibit any synergistic effect on ACTH secretion. We conclude OSM has a stimulatory effect on ACTH secretion in normal rat pituitary cell cultures, and OSM acts mainly on corticotroph, supporting the potential role of OSM to modulate immune-endocrine regulation in the pituitary.

Effects of oncostatin M on hormone release of rat pituitary cells in primary culture

It has become increasingly clear that cytokines play an important role in modulating neuroendocrine regulation, especially in the secretion of corticotropin (ACTH) in the pituitary. Oncostatin M (OSM), a cytokine of IL-6 family has been reported to increase ACTH secretion and pro-opiomelanocortin (POMC) transcription in murine corticotroph pituitary tumor cells (AtT20 cells). The present study was undertaken to determine the effects of OSM on hormonal release in primary culture of rat pituitary cells. Growth hormone or prolactin release was not affected by OSM. OSM (1 nM) stimulated ACTH release (35.1% increase versus control, p>0.001) in dispersed pituitary cells of rat to a lesser extent than in AtT20 cells. Corticotropin releasing hormone (CRH) (10 nM) also induced a 2.3-fold increase of ACTH secretion (p>0.001), but co-treatment of OSM and CRH did not exhibit any synergistic effect on ACTH secretion. We conclude OSM has a stimulatory effect on ACTH secretion in normal rat pituitary cell cultures, and OSM acts mainly on corticotroph, supporting the potential role of OSM to modulate immune-endocrine regulation in the pituitary.

Lactation inhibits the potentiating effect of galanin upon the GnRH-induced LH release observed in diestrous-1 rat

Recent demonstrations of no changes in hypothalamic gonadotropin releasing hormone (GnRH) gene expression nd GnRH levels detected at the pituitary gland in diestrous and lactating rats, indicate that lactational hypogonadotropism in this species is not associated with inhibition of hypothalamic GnRH synthesis and secretion. Hypothalamic galanin potentiates GnRH effects on luteinizing hormone (LH) secretion in male and cycling rats. To explore the interaction between GnRH and galanin during lactation, we studied in vitro the effects of pulsatile stimulation with those peptides upon LH synthesis and secretion from rat pituitaries on diestrous 1 or day 10 of lactation. Hemipituitaries were separately incubated in 1 ml Dulbecco's Minimal Essential Medium supplemented with 1 per cent penicillin-streptomycin and fetal calf serum, at 37 degrees Celsius in 5 per cent CO2-air. The hemipituitaries were stimulated during 12 h with hourly pulses, 6 min each, of (a) gonadotropin releasing hormone (GnRH 25 ng/pulse), (b) rat galanin (600 ng/pulse), (c) GnRH plus galanin, or (d) saline. Medium was collected before each pulse to determine LH by radioimmunoassay. After the 12 h pulsatile regime total RNA was extracted and both actin and beta-LH mRNA were determined by reverse transcriptase polymerase chain reaction. There was a significant stimulation of LH secretion by GnRH (ANOVA, p<0.001) without significant differences between diestrous and lactation pituitaries. Galanin alone did not modify LH secretion but it potentiated the effect of GnRH upon pituitaries from diestrous (p=0.036) but not lactating rats. Neither peptide alone or its combination modified pituitary beta-LH mRNA levels. Results show that galanin regulates differently the secretion and synthesis of LH at the pituitary level. The disappearance of galanin-induced potentiation of GnRH effects upon LH secretion during lactation might contribute to the hypogonadotropism of lactation in the rat.

Dose-dependent effects of 17-beta-estradiol on pituitary thyrotropin content and secretion in vitro

We studied the basal and thyrotropin-releasing hormone (TRH) (50 nM) induced thyrotropin (TSH) release in isolated hemipituitaries of ovariectomized rats treated with near-physiological or high doses of 17-Beta-estradiol benzoate (EB; sc, daily for 10 days) or with vehicle (untreated control rats, OVX). One group was sham-operated (normal control). The anterior pituitary glands were incubated in Krebs-Ringer bicarbonate medium, pH 7.4 at 37 C in an atmosphere of 95 percent O2/5 percent CO2. Medium and pituitary TSH was measured by specific RIA (NIDDK-RP-3). Ovariectomy induced a decrease (P<0.05) in basal TSH release (normal control = 44.1 + 7.2; OVX = 14.7 + 3.0 ng/ml) and tendend to reduce TRH-stimulated TSH release (normal control = 33.0 + 8.1; OVX = 16.6 + 2.4 ng/ml). The lowest dose of EB (0.7 mug/100 g body weight) did not reverse this alteration, but markedly increased the pituitary TSH content (0.6 + 0.06 mug/hemipituitary; P<0.05) above that of OVX (0.4 + 0.03 mug/hemipituitary) and normal rats (0.46 + 0.03 mug/hemipituitary). The intermediate EB dose (1.4 mug/100 g body weight) induced a nonsignificant tendency to a higher TSH response to TRH compared to OVX and a lower response compared to normal rats. Conversely, in the rats treated with the highest dose (14 mug/100 g body weight), serum 17-Beta-estradiol was 17 times higher than normal, and the basal and TRH-stimulated TSH release, as well as the pituitary TSH content, was significantly (P<0.05) reduced compared to normal rats and tended to be even lower than the values observed for the vehicle-treated OVX group, suggesting an inhibitory effect of hyperestrogenism. In conclusion, while reinforcing the concept of a positive physiological regulatory role of estradiol on the tSH response to TRH and on the pituitary stores of the hormone, the present results suggest an inhibitory effect of high levels of estrogen on these responses.

Effects of bromocriptine on serum prolactin levels, pituitary weight and immunoreactive prolactin cells in estradiol-treated ovariectomized rats: an experimental model of estrogen-dependent hyperprolactinemia

The present study was designed to assess the effects of bromocriptine, a dopamine agonist, on pituitary wet weight, number of immunoreactive prolactin cells and serum prolactin concentrations in estradioltreated rats. Ovariectomized Wistar rats were injected subcutaneously with sunflower oil vehicle or estradiol valerate (50 or 300 mug rat-1 week-l) for 2, 4 or 10 weeks. Bromocriptine (0.2 or 0.6 mg rat-1 day-l) was injected daily during the last 5 or 12 days of estrogen treatment. Data were compared with those obtained for intact control rats. Administration of both doses of estrogen increased serum prolactin levels. No difference in the number of prolactin cells in rats treated with 50 mug estradiol valerate was observed compared to intact adult animals. In contrast, rats treated with 300 mug estradiol valerate showed a significant increase in the number of prolactin cells (P<0.05). Therefore, the increase in serum prolactin levels observed in rats treated with 50 mug estradiol valerate, in the absence of morphological changes in the pituitary cells, suggests a "functional" estrogen-induced hyperprolactinemia. Bromocriptine decreased prolactin levels in all estrogen-treated rats. The administration of this drug to rats previously treated with 300 mug estradiol valerate also resulted in a significant decrease in pituitary weight and number of prolactin cells when compared to the group treated with estradiol alone. The general antiprolactinemic and antiproliferative pituitary effects of bromocriptine treatment reported here validate the experimental model of estrogen-induced hyperprolactinemic rats.